LogoCrystal's MCW Coder Hub

cytology

4 min read

CYTOLOGY - Medical Keyword Reference

Cytology is the microscopic examination and study of individual cells and small cell clusters obtained from body fluids, secretions, or tissue scrapings to diagnose diseases, particularly cancer.[web:knowledge]

Short and Long Definitions

Short definition Cytology is the microscopic study of cells obtained from body sites to detect disease, inflammation, or malignancy.

Long definition Cytology is the branch of pathology focused on examining individual cells and small tissue fragments under microscopy to evaluate cellular morphology, architecture, nuclear characteristics, and cytoplasmic features for diagnostic purposes; obtained via exfoliative methods (cervical Pap smear, urine, sputum, effusions), fine needle aspiration (FNA), brushings, or washings; used primarily for cancer screening/diagnosis (cervical, thyroid, breast), infectious disease identification, and benign/inflammatory condition assessment; advantages include minimal invasiveness, rapid results, and cost-effectiveness compared to surgical biopsy, though limitations include inability to assess tissue architecture and occasional need for follow-up histopathology.

Etymology

  • Cyto-: Greek kútos (κύτος) = “container, hollow vessel” (referring to cell).
  • -logy: Greek -logía (-λογία) = “study of” (from lógos “word, study”).
  • Literal: “Study of cells.”
  • Historical note: Term coined in the 19th century; modern cytology developed with Papanicolaou’s cervical cancer screening technique (1928).

Classification of Cytology Types

TypeMethod/SpecimensPrimary Applications
Exfoliative cytologySpontaneously shed cells (Pap smear, sputum, urine, pleural/peritoneal fluid).Cervical cancer screening, bladder cancer, mesothelioma, infectious disease.
Aspiration cytology (FNA)Fine needle aspiration biopsy.Thyroid nodules, breast masses, lymph nodes, salivary glands.
Brush cytologyEndoscopic brushings.Biliary/pancreatic duct, bronchial, esophageal lesions.
Imprint/touch prepDirect tissue impression on slide.Intraoperative lymph node assessment.
Liquid-based cytologyThinPrep, SurePath (monolayer preparation).Cervical screening (improved Pap smear).

Coding Context

CPT Codes (Cytopathology):

CodeDescription
88104Cytopathology, fluids, washings or brushings (except cervical/vaginal); smears w/interpretation.
88108Cytopathology, concentration technique (e.g., Saccomanno), smears and interpretation.
88112Cytopathology, selective cellular enhancement technique w/interpretation (liquid-based).
88142-88143Cytopathology, cervical/vaginal (Pap smear) automated/manual screening.
88172-88173Fine needle aspiration, evaluation of smears/cell block.
88177FNA immediate cytohistologic study to determine adequacy.
88305Surgical pathology, gross and microscopic (if cell block processed as tissue).

ICD-10-CM (Diagnoses):

CodeDescription
R87.619Unspecified abnormal cytological findings in cervical specimens (Pap).
R87.810Cervical high-risk HPV DNA positive.
R84.9Abnormal findings in respiratory system specimens (sputum cytology).
R89.7Abnormal cytological findings in other body fluids (pleural, peritoneal).
C73Malignant neoplasm of thyroid (thyroid FNA diagnosis).

Common Cytology Procedures and Applications

Cervical/Vaginal cytology (Pap smear):

  • Screening: Cervical cancer and precursor lesions (CIN, dysplasia).
  • Classification: Bethesda System (NILM, ASC-US, ASC-H, LSIL, HSIL, carcinoma).
  • Codes: 88142 (automated screen), 88143 (manual screen), 88164-88167 (physician interpretation).

Fine Needle Aspiration (FNA):

  • Thyroid: Evaluate nodules (Bethesda classification I-VI: nondiagnostic to malignant).
  • Breast: Palpable masses, cysts.
  • Lymph nodes: Lymphoma, metastases.
  • Salivary glands: Pleomorphic adenoma, Warthin tumor.

Body fluid cytology:

  • Pleural/peritoneal effusions: Malignancy (adenocarcinoma, mesothelioma) vs. benign.
  • Cerebrospinal fluid (CSF): Meningitis, lymphoma.
  • Urine: Bladder cancer (urothelial carcinoma).
  • Sputum: Lung cancer screening (historically; now replaced by CT).
  • Histology: Study of tissue architecture (complementary to cytology).
  • Histopathology: Microscopic examination of diseased tissue.
  • Cytopathology: Subspecialty of pathology focused on cellular diagnosis.
  • FNA (Fine Needle Aspiration): Minimally invasive cytology sampling technique.
  • Cell block: Cytology specimen processed as tissue for immunohistochemistry/architecture.
  • Pap smear: Cervical cytology screening test (named after George Papanicolaou).
  • Bethesda System: Standardized reporting for cervical and thyroid cytology.
  • ThinPrep/SurePath: Liquid-based cytology platforms.
  • Immunocytochemistry (ICC): Antibody staining on cytology specimens.

Cytologic Diagnostic Criteria

Malignancy indicators:

  • High nuclear-to-cytoplasmic ratio.
  • Nuclear pleomorphism, hyperchromasia.
  • Irregular nuclear membranes, chromatin clumping.
  • Prominent/multiple nucleoli.
  • Mitotic figures.
  • Loss of cohesion (single malignant cells vs. cohesive benign clusters).

Benign vs. malignant features:

  • Benign: Uniform cells, low N:C ratio, cohesive groups, smooth nuclear borders.
  • Malignant: Irregular cells, high N:C ratio, discohesive, irregular nuclei.

Advantages and Limitations

Advantages:

  • Minimally invasive (no surgical excision).
  • Rapid diagnosis (often same-day for FNA).
  • Cost-effective screening tool.
  • Useful for deep/inaccessible lesions (ultrasound/CT-guided FNA).
  • Can be repeated easily.

Limitations:

  • Cannot assess tissue architecture/invasion (histology required).
  • Sampling error (may miss lesion).
  • Limited material for ancillary studies (flow cytometry, molecular).
  • Requires skilled cytopathologist interpretation.
  • Indeterminate/atypical categories may require surgical biopsy.

Clinical Details

Specimen adequacy criteria (thyroid FNA Bethesda):

  • Adequate: ≥6 groups of well-preserved follicular cells, each with ≥10 cells.
  • Unsatisfactory: Inadequate cellularity, obscuring blood/artifact.

Cervical cytology screening guidelines (USPSTF):

  • Age 21-29: Pap every 3 years.
  • Age 30-65: Pap + HPV co-testing every 5 years OR Pap alone every 3 years.
  • Age >65: Discontinue if adequate prior screening.

Quality assurance:

  • CLIA-regulated (Clinical Laboratory Improvement Amendments).
  • Rescreening of negative cases (10% random review).
  • Correlation with histology for discrepancies.

Historical Context

  • 1928: George Papanicolaou develops Pap smear for cervical cancer screening.
  • 1950s-1960s: Widespread adoption of Pap smear; cervical cancer mortality decreases dramatically.
  • 1988: Bethesda System standardizes cervical cytology reporting.
  • 1996: Liquid-based cytology (ThinPrep) FDA approved.
  • 2000s: Thyroid FNA Bethesda System introduced.

One-Sentence Summary

Cytology (Greek kytos-logia “cell study”), microscopic examination of exfoliated/aspirated cells (Pap 88142, FNA 88172-88173) for cancer screening/diagnosis (cervical R87.619, thyroid C73), offers minimally invasive rapid diagnosis via morphologic assessment though lacks tissue architecture context requiring histologic confirmation for indeterminate cases.

Document created: February 13, 2026 Medical coding professional reference

Med roots Appendix A Prefixes Appendix B Combining Forms Appendix C Suffixes Appendix D Suffix forms

Graph View

Recent Notes